| Mary S Grasmick, LCSW | |
|
1981 E Palmer Wasilla Hwy Ste 200, Wasilla, AK 99654-7287 | |
| (907) 802-2493 | |
| Not Available |
| Full Name | Mary S Grasmick |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1981 E Palmer Wasilla Hwy Ste 200, Wasilla, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093386559 | NPI | - | NPPES |
| L10467 | Other | OR | LCSW LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | L10467 (Oregon) | Primary |
| Entity Name | Sokyahealth Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447842232 PECOS PAC ID: 9739575648 Enrollment ID: O20220401000312 |
News Archive
Boston Children's Museum announced today the second Lunch & Learn in a series of lectures which focus on helping parents, educators and child caregivers understand and react to the most prevalent issues facing our children.
The International Sweeteners Association welcomes the publication this month of a new scientific report by Ashwell et al. in Nutrition Research Reviews.
The Guardian examines the challenge of testing and treating some of the estimated 1.4 million people living with HIV/AIDS in Kenya. "Deep-rooted stigma and patchy health education has led many to cower from the disease, which has seen the country's life expectancy rates shortened by 20 years in the last two decades," the newspaper writes. Even though "[t]he country's government has supplied antiretroviral therapy (ART) to suppress the virus to patients for free since 2006, … of the 390,000 adults estimated as being eligible for ART at the time of the survey, around 140,000, or 35%, were taking the medication," according to a 2007 country survey.
A new drug discovery system allows scientists to specifically target members of an important family of enzymes, called phosphatases, which were previously considered mostly "undruggable".
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary S Grasmick, LCSW 1981 E Palmer Wasilla Hwy Ste 200, Wasilla, AK 99654-7287 Ph: (907) 802-2493 | Mary S Grasmick, LCSW 1981 E Palmer Wasilla Hwy Ste 200, Wasilla, AK 99654-7287 Ph: (907) 802-2493 |
News Archive
Boston Children's Museum announced today the second Lunch & Learn in a series of lectures which focus on helping parents, educators and child caregivers understand and react to the most prevalent issues facing our children.
The International Sweeteners Association welcomes the publication this month of a new scientific report by Ashwell et al. in Nutrition Research Reviews.
The Guardian examines the challenge of testing and treating some of the estimated 1.4 million people living with HIV/AIDS in Kenya. "Deep-rooted stigma and patchy health education has led many to cower from the disease, which has seen the country's life expectancy rates shortened by 20 years in the last two decades," the newspaper writes. Even though "[t]he country's government has supplied antiretroviral therapy (ART) to suppress the virus to patients for free since 2006, … of the 390,000 adults estimated as being eligible for ART at the time of the survey, around 140,000, or 35%, were taking the medication," according to a 2007 country survey.
A new drug discovery system allows scientists to specifically target members of an important family of enzymes, called phosphatases, which were previously considered mostly "undruggable".
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
› Verified 2 days ago
Miss Robin Bayard Hughes, LMSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1363 W Spruce Ave, Wasilla, AK 99654 Phone: 907-376-2411 Fax: 907-352-3363 | |
Ms. Kim-sandy Kline, L.C.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4900 E Palmer Wasilla Hwy, Suite 120, Wasilla, AK 99654 Phone: 907-982-2146 | |
Amanda Mae Rose, MSSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3223 E Palmer Wasilla Hwy Ste 4, Wasilla, AK 99654 Phone: 907-631-6300 | |
Dr. Ann Marie Yaros, PH.D. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1261 S Seward Meridian Rd, Wasilla, AK 99654 Phone: 907-357-7550 | |
Lorelei Crewdson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1363 W Spruce Ave, Wasilla, AK 99654 Phone: 907-352-3252 | |
Isaac Dine'h Winters, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 301 E Danna Ave, Wasilla, AK 99654 Phone: 907-357-7519 |